Improvement of cure after hematopoietic stem cel transplantations in children
DOI:
https://doi.org/10.12775/MBS.2016.009Keywords
hematopoietic stem cells, high-dose therapy, stem cell transplantation, children, adolescents and young adultsAbstract
Background. Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system, including malignancies, bone marrow failure syndromes, disorders of the immune system, and metabolic disorders.
Objective. Analysis of results of hematopoietic stem cell transplantations performed over a period of 12 years in a single pediatric center.
Patients and methods. All transplants performed between 2003 and 2015 in the Department of Pediatric Hematology and Oncology in Bydgoszcz were included in this analysis. The results of therapy with stem cell transplantation were analyzed in three time periods: 2004-2007, 2008-2011 and 2012-2015.
Results. A total number of transplants was 318, including 132 auto-HSCT and 186 allo-HSCT. Among allogeneic transplants, 68 were done from matched-sibling donor and 118 from alternative donor. The mean survival for all patients estimated by Kaplan-Meier method was 8.1 years. Probability of overall survival (pOS) after all transplants was 0.64±0.03. pOS after allo-HSCT was 0.62±0.04, and 0.67±0.05 after auto-HSCT. Overall survival for patients transplanted in the second (2008-2011) and third (2012-2015) time period was comparable both for auto- and allo-HSCT. However, it was significantly higher than for patients transplanted in the first period of time (2004-2007) for all patients, and for those undergoing auto-HSCT. In allo-HSCT patients, in spite of increase of over 20% in pOS (43% vs 66% vs 64% in respective time periods), the difference was not statistically significant.
Conclusion. Presented results of HSCT obtained in our center are comparable with those from other international registries and centers.References
Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D; Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015; 2(3): e91-e100.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.20 (Epub ahead of print).
Biuletyn informacyjny Poltransplant. Warszawa, 2015;23(1): 76-84.
Styczyński J, Dębski R, Krenska A, et al. Transplantacje komórek hematopoetycznych w świetle 5-letnich doświadczeń. Med Biol Sci, 2008; 22 (3): 157-163.
Gmerek A, Styczyński J, Krenska A, et al. Pneumonia in hematopoietic stem cell recipients during early post-transplant period. Med Biol Sci, 2009; 23 (3): 39-43.
Styczyński J, Gil L. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant, 2008; 42 (suppl 2): S77-S81.
Styczynski J, Reusser P, Einsele H, et al. Management of herpes simplex, varicella-zoster and Epstein-Barr virus infection in patients with hematological malignancies and after stem cell transplantation. Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant, 2009; 43: 757-770
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, de Elvira CR, Snowden JA, Passweg J, Apperley J, Niederwieser D, Stijnen T, Brand R. Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine. 2015;2(12):2101-9.
Pasquini MC, Zhu X. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2015. Available at: http://www.cibmtr.org.
Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57:794-802.
Czyzewski K, Debski R, Krenska A, Wysocki M, Styczynski J. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis. Anticancer Res. 2014;34:7379-7382.
Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327-40.
Styczynski J, Balduzzi A, Gil L, Labopin M, Hamladji RM, Marktel S, Yesilipek MA, Fagioli F, Ehlert K, Matulova M, Dalle JH, Wachowiak J, Miano M, Messina C, Diaz MA, Vermylen C, Eyrich M, Badell I, Dreger P, Gozdzik J, Hutt D, Rascon J, Dini G, Peters C. Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood. 2012;119:2935-2942.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 251
Number of citations: 0